Day One Biopharmaceuticals Reports Strong Preliminary 2025 Revenue, Robust 2026 Guidance, and Key Pipeline Progress

summarizeSummary

Day One Biopharmaceuticals announced strong preliminary 2025 OJEMDA net product revenue and provided optimistic 2026 guidance, alongside a robust cash position and key pipeline advancements.

check_boxKey Events

• Strong Preliminary 2025 Revenue

  Reported preliminary unaudited OJEMDA net product revenue of approximately $155.4 million for the full year 2025, representing 172% year-over-year growth.

• Optimistic 2026 Revenue Guidance

  Projected 2026 OJEMDA U.S. net product revenue to be between $225 million and $250 million, indicating 53% year-over-year growth at the midpoint.

• Robust Cash Position

  Held approximately $441.1 million in cash, cash equivalents, and short-term investments as of December 31, 2025, prior to the Mersana acquisition.

• Key Pipeline Milestones Announced

  Expects to complete enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial for tovorafenib in front-line pLGG in the first half of 2026, with initial data from the Phase 1a trial for DAY301 in the second half of 2026, and Phase 1 data for Emi-Le by mid-2026.

auto_awesomeAnalysis

Day One Biopharmaceuticals has reported strong preliminary unaudited net product revenue for 2025, significantly exceeding prior year performance. The company also provided robust revenue guidance for 2026, indicating continued commercial momentum for OJEMDA. Coupled with a solid cash position, these financial updates provide a strong foundation. Furthermore, the company outlined critical pipeline milestones, including the expected completion of enrollment for the pivotal FIREFLY-2 trial, which could substantially expand OJEMDA's market opportunity, and upcoming data readouts for its Emi-Le and DAY301 programs. This combination of strong commercial execution, healthy financials, and clear development catalysts positions the company for continued growth.